RNAC Q2 2021 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M

Gross Profit

$20M100.0% margin

Operating Income

$452,0002.3% margin

Net Income

$5M23.2% margin

EPS (Diluted)

$1.13

QoQ Revenue Growth

+77.9%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$181M

Total Liabilities

$185M

Stockholders' Equity

-$4M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$0	—
Gross Profit	$20M	$0	—
Operating Income	$452,000	-$16M	+102.8%
Net Income	$5M	-$24M	+119.0%